Progressive and incurable, Alzheimer’s disease affects an estimated 6.7 million U.S. adults at least 65 years old, according ...

Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time.

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has notified BioArctic that the first sales milestone according to the licensing agreement has been reached. The milestone was reached as ...

Biogen Inc (NASDAQ:BIIB) reported fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35. The company ...

Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...

Alzheimer's patients with a baseline CDR-SB score of 3.5 could expect approximately 4 additional months (95% CI 2-7 months) ...

Biogen and Eisai have spent much of Leqembi’s launch convincing physicians and patients that it’s safe to treat Alzheimer’s ...

Eisai announces Leqembi sales reaches €200 million; BioArctic to receive €10 million payment: Stockholm, Sweden Wednesday, February 19, 2025, 14:00 Hrs [IST] BioArctic AB’s ...

Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...

Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...